Macro Group Pharmaceutical SAE

Macro Group Pharmaceutical S.A.E has a market price of 1.805 EGP per share, with a market capitalization of 6,175,335,918.48 EGP. The company's price-to-earnings ratio is 53.36, and its price-to-book ratio is 31.89, indicating a high valuation relative to its book value. The enterprise value to EBITDA ratio is 47.83, and the enterprise value to revenue ratio is 7.24, suggesting a moderate valuation relative to its revenue. The company's profitability is reflected in its return on equity of 59.76% and return on assets of 14.88%, which are strong indicators of efficient use of equity and assets. However, the company's debt-to-equity ratio of 1.72 suggests a relatively high level of leverage, which could pose a risk in a downturn. Macro Group Pharmaceutical S.A.E's revenue is concentrated in its core cosmeceutical and herbal drug products, with no significant diversification into other segments. The company's geographic exposure is primarily within Egypt, with no disclosed international operations. This concentration could limit its growth potential and increase its vulnerability to local economic conditions. The company's growth trajectory is reflected in its current FY outlook, which shows a revenue of 894,544,710 EGP. The next FY outlook is not provided, but the company's operating cash flow of 160,986,150 EGP and free cash flow of 90,851,310 EGP indicate a strong cash generation capability. The capital expenditure of -42,477,070 EGP suggests a reduction in investment, which could affect future growth. The company faces a medium liquidity risk, as indicated by its current ratio of 1.35, which is slightly above 1 but not significantly so. The risk assessment also notes that net cash is negative after subtracting total debt, which could affect the company's ability to meet short-term obligations. The dilution risk is low, with no significant dilution potential identified. Recent events and filings do not indicate any major changes in the company's operations or financial position. The company's ESG controversies score is 100.0, indicating no controversies, while its governance and social pillars are 16.7 and 18.7, respectively, suggesting room for improvement in these areas.